- Home
- IFRX vs FSP Comparison
IFRX vs FSP Comparison
Compare IFRX & FSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IFRX | FSP |
|---|---|---|
| Founded | 2007 | 1981 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 72.4M |
| IPO Year | 2017 | 2001 |
Fundamental Metrics
Financial Performance| Metric | IFRX | FSP |
|---|---|---|
| Price | $1.01 | $0.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 390.2K | ★ 551.1K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 6.03% |
| EPS Growth | N/A | ★ 15.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $107,162,000.00 |
| Revenue This Year | $3,018.21 | $17.91 |
| Revenue Next Year | $91.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.56 |
| 52 Week High | $1.94 | $1.88 |
Technical Indicators
Market Signals| Indicator | IFRX | FSP |
|---|---|---|
| Relative Strength Index (RSI) | 58.33 | 48.39 |
| Support Level | $0.96 | $0.56 |
| Resistance Level | $1.11 | $0.71 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 77.72 | 62.95 |
Price Performance
Historical ComparisonAbout IFRX InflaRx N.V.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.